Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

about

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Item

http://www.wikidata.org/entity/Q50200754

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@en

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@nl

type

Item

label

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@en

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@nl

prefLabel

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@en

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@nl

P1476

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

@en

P2093

Aimee L Kenoyer

http://www.w3.org/2001/XMLSchema#string

Amelia Waltman

http://www.w3.org/2001/XMLSchema#string

Brian G Till

http://www.w3.org/2001/XMLSchema#string

D Scott Wilbur

http://www.w3.org/2001/XMLSchema#string

Damian J Green

http://www.w3.org/2001/XMLSchema#string

Darrell R Fisher

http://www.w3.org/2001/XMLSchema#string

Donald K Hamlin

http://www.w3.org/2001/XMLSchema#string

Johnnie J Orozco

http://www.w3.org/2001/XMLSchema#string

Mark D Hylarides

http://www.w3.org/2001/XMLSchema#string

Shyril O'Steen

http://www.w3.org/2001/XMLSchema#string

P2860

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option

Radioimmunotherapy of human tumours

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Drug combination studies and their synergy quantification using the Chou-Talalay method

Postibrutinib outcomes in patients with mantle cell lymphoma.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

P304

3885-3893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-17-0082

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ajay K Gopal

Oliver W Press

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28566329

http://www.w3.org/2001/XMLSchema#string

P932

5560265

http://www.w3.org/2001/XMLSchema#string